Skip to main content

Advertisement

Table 6 Occurrence of haematological Grade 3–4 adverse events across treatment cycles

From: Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

Preferred term Cycles 1–2 Cycles 3–4 Cycles 5–6 Cycles 7+
AZA (N = 128) CCR (N = 130) AZA (n = 89) CCR (n = 61) AZA (n = 75) CCR (n = 25) AZA (n = 57) CCR (n = 17)
Any Grade 3–4 TEAE, n (%) 83 (65) 99 (76) 47 (53) 35 (57) 33 (44) 8 (32) 37 (65) 13 (77)
Febrile Neutropenia, n (%) 23 (18) 34 (26) 7 (8) 7 (12) 4 (5) 3 (12) 3 (5) 2 (12)
Thrombocytopenia, n (%) 24 (19) 26 (20) 11 (12) 8 (13) 8 (11) 0 9 (16) 0
Neutropenia, n (%) 16 (13) 20 (15) 10 (11) 9 (15) 3 (4) 2 (8) 12 (21) 5 (29)
Anaemia, n (%) 17 (13) 21 (16) 3 (3) 3 (5) 1 (1) 0 5 (9) 0
  1. Safety evaluable patients received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. Patients who received BSC only were included in safety assessments if they had at least 1 post-randomisation safety assessment